Evidence map›Paper›PMID 17914406›Full record

ArticleGene therapy2007

Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors.

J-P Louboutin, L Agrawal, B A S Reyes, E J Van Bockstaele, D S Strayer

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. p53 as a retrovirus-induced oxidative stress modulator.The Journal of general virology · 2015
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2011
    Article
  14. Editorial neuroAIDS review.AIDS (London, England) · 2011
    Review
  15. Gene transfer to the cerebellum.Cerebellum (London, England) · 2010
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J-P LouboutinDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA. jplouboutin@hotmail.com
L Agrawal
B A S Reyes
E J Van Bockstaele
D S Strayer
Thomas Jefferson University · US

Funding

Use of SV40 derived vectors to inhibit HIV 1 infectionP01AI048244 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI STRAYER, DAVID S · 2000 to 2003
$3.3M
Targeting HIV infection of the cns using gene deliveryR01MH070287 · NIMH · THOMAS JEFFERSON UNIVERSITY · PI STRAYER, DAVID S · 2004 to 2008
$1.9M
PROTECTING CNS CELLS FROM HIV AND HIV-INDUCED INJURYR21MH069122 · NIMH · THOMAS JEFFERSON UNIVERSITY · PI STRAYER, DAVID S · 2003 to 2004
$314k
NIAID NIH HHS AI48244NIMH NIH HHS MH69122NIMH NIH HHS MH70287
6 · The paper itself

Abstract

Human immunodeficiency virus-1 (HIV-1) is the most frequent cause of dementia in adults under 40. We sought to use gene delivery to protect from HIV-1-related neuron loss. Because HIV-1 envelope (Env) gp120 elicits oxidant stress and apoptosis in cultured neurons, we established reproducible parameters of Env-mediated neurotoxicity in vivo, then tested neuroprotection using gene delivery of antioxidant enzymes. We injected 100-500 ng mul(-1)gp120 stereotaxically into rat caudate-putamens (CP) and assayed brains for apoptosis by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) 6-h to 14-day post-injection. Peak apoptosis occurred 1 day after injection of 250 and 500 ng microl(-1)gp120. TUNEL-positive cells mostly expressed neuronal markers (NeuroTrace), although some expressed CD68 and so were most likely microglial cells. Finally, we compared neuroprotection from gp120-induced apoptosis provided by localized and generalized intra-central nervous system (CNS) gene delivery. Recombinant SV40 vectors carrying Cu/Zn superoxide dismutase (SOD1) or glutathione peroxidase (GPx1) were injected into the CP, where gp120 was administered 4-24 weeks later. Alternatively, we inoculated the vector into the lateral ventricle (LV), with or without prior intraperitoneal (i.p.) administration of mannitol. Intracerebral injection of SV(SOD1) or SV(GPx1) significantly protected neurons from gp120-induced apoptosis throughout the 24-week study. Intraventricular vector administration protected from gp120 neurotoxicity comparably, particularly if preceded by mannitol i.p. Thus, HIV-1 gp120 is neurotoxic in vivo, and intracerebral or intra-ventricular administration of rSV40 vectors carrying antioxidant enzymes is neuroprotective. These findings suggest the potential utility of both localized and widespread gene delivery in treating neuroAIDS and other CNS diseases characterized by excessive oxidative stress.

Indexed as

HIV-1AIDS Dementia ComplexAnimalsAntioxidantsApoptosisBrainFemaleGenetic TherapyGenetic VectorsGlutathione PeroxidaseHIV Envelope Protein gp120HumansInjectionsInjections, IntraventricularModels, AnimalNeuronsAntioxidantsGlutathione PeroxidaseHIV Envelope Protein gp120Superoxide Dismutase

Identifiers

PMID17914406
OpenAlexW2007066597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.